Pathophysiology of leg ulceration

Venous and Lymphatic Diseases

Volumn , Issue , 2006, Pages 355-369

  Pappas, Peter J ^a   Lal, Brajesh K ^a   Duran, Walter N ^a   Padberg, Frank T ^b   Zickler, Robert W ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249738437     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (63)

1. White GH. Chronic venous insufficiency. In: Veith F, Hobson RW, II, Williams RA, Wilson SE, eds. Vascular Surgery. New York: McGraw-Hill Inc, 1993:865-888.
2. Callam MJ. Epidemiology of varicose veins. Br J Surg 1994; 81:167-173.
3. Hume M. Presidential address: a venous renaissance? J Vasc Surg 1992; 6:947-951.
4. Lawrence PF, Gazak CE. Epidemiology of chronic venous insufficiency. In: Gloviczki P, Bergan JJ, eds. Atlas of Endoscopic Perforator Vein Surgery. London: Springer-Verlag, 1998:31-44.
5. Porter JM. International Consensus Committee on Chronic Venous Disease. Reporting Standards in venous disease: an update. J Vasc Surg 1995; 21:635-645.
6. Varicose veins: pathology. In: Browse NL, Burnand KG, Irvine AT, Wilson NM, eds. Diseases of the Veins. London and New York: Oxford University Press, 1999:145-162.
7. Gunderson J, Hauge M. Hereditary factors in venous insufficiency. Angiology 1969; 20:346-355.
8. Cornu-Thenard A, Boivin P, Baud MM, De Vincenzi I, Carpentier PH. Importance of the familial factor in varicose disease: clinical study of 134 families. J Derm Surg Onc 1994; 20:318-326.
9. Labropoulos N, Giannoukas AD, Delis K, et al. Where does the venous reflux start. J Vasc Surg 1997; 26:736-742.
10. Wakefield TM, Strietert RM, Prince MR, Downing LJ, Greenfield LJ. Pathogenesis of venous thrombosis: a new insight. Cardiovasc Surg 1997; 5:6-15.
11. Takase S, Bergan JJ, Schmid-Schonbein G. Expression of adhesion molecules and cytokines on saphenous veins in chronic venous insufficiency. Ann Vasc Surg 2000; 14:427-135.
12. Rose A. Some new thoughts on the etiology of varicose veins. J Cardiovasc Surg 1986; 27:534-543.
13. Pappas PJ, Gwertzman GA, DeFouw DO, et al. Retinoblastoma protein: a molecular regulator of chronic venous insufficiency. J Surg Res 1998; 76:149-153.
14. Travers JP, Brookes CE, Evans J, et al. Assessment of was structure and composition of varicose veins with reference to collagen, elastin and smooth muscle content. Eur J Vasc Endovasc Surg 1996; 11:230-237.
15. Jurukova Z, Milenkov C. Ultrastructural evidence for collagen degradation in the walls of varicose veins. Exp and Molec Path 1982; 37:37-47.
16. Venturi M, Bonavina L, Annoni F, et al. Biochemical assay of collagen and elastin in the normal and varicose vein wall. J Surg Res 1996; 60:245-248.
17. Maurel E, Azema C, Deloly J, Bouissou H. Collagen of the normal and the varicose human saphenous vein: a biochemical study. Clinica Chimica Acta 1990; 193:27-38.
18. Ascher E, Jacob T, Hingorani A, Gunduz Y, Mazzariol F, Kallakuri S. Programmed cell death (Apoptosis) and its role in the pathogenesis of lower extremity varicose veins. Ann Vasc Surg 2000; 14:24-30.
19. Ascher E, Jacob T, Hingorani A, Tsemekhin B, Gunduz Y. Expression of molecular mediators of apoptosis and their role in the pathogenesis of lower-extremity varicose veins. J Vasc Surg 2001; 33:1080-1086.
20. Gandhi RH, Irizarry E, Nachman GB, Halpern JJ, Mulcare RJ, Tilson MD. Analysis of the connective tissue matrix and proteolytic activity of primary varicose veins. J Vasc Surg 1993; 18:814-820.
21. Parra JR, Cambria RA, Hower CD, et al. Tissue inhibitor of metalloproteinase-1 is increased in the saphenofemoral junction of patients with varices in the leg. J Vasc Surg 1998; 28:669-675.
22. Kosugi I, Urayama H, Kasashima F, Ohtake H, Watanabe Y. Matrix metalloproteinase-9 and urokinase-type plasminogen activator in varicose veins. Ann Vasc Surg 2003; 17:234-238.
23. Woodside KJ, Hu M, Burke A, et al. Morphologic characteristics of varicose veins: Possible role of metalloproteinases. J Vasc Surg 2003; 38:162-169.
24. Shireman PK, McCarthy WJ, Pearce WH, et al. Plasminogen activator levels are influenced by location and varicosity in greater saphenous vein. J Vasc Surg 1996; 24:719-724.
25. Badier-Commander C, Verbeuren T, Lebard C, Michel J, Jacob M. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Path 2000; 192:105-112.
26. Lowell RC, Gloviczki P, Miller VM. In vitro evaluation of endothelial and smooth muscle function of primary varicose veins. J Vasc Surg 1992; 16:679-686.
27. Rizzi A, Quaglio D, Vasquez G, et al. Effects of vasoactive agents in healthy and diseased human saphenous veins. J Vasc Surg 1998; 28:855-861.
28. Barber DA, Wang X, Gloviczki P, Miller VM. Characterization of endothelin receptors in human varicose veins. J Vasc Surg 1997; 26:61-69.
29. Nemcova S, Gloviczki P, Rud KS, Miller VM. Cyclic nucleotides and production of prostanoids in human varicose veins. J Vasc Surg 1999; 30:876-884.
30. Homans J. The etiology and treatment of varicose ulcer of the leg. SG&O 1917; 24:300-311.
31. Blalock A. Oxygen content of blood in patiens with varicose veins. Arch Surg 1929; 19:898-905.
32. Pratt GH. Arterial varices; a syndrome. Am J Surg 1949; 77:456-460.
33. Burnand KG, Whimster I, Naidoo A, Browse NL. Pericapillary fibrin deposition in the ulcer bearing skin of the lower limb: the cause of lipodermatosclerosis and venous ulceration. Br Med J 1982; 285:1071-1072.
34. Burnand KG, Clemenson G, Gaunt J, Browse NL. The effect of sustained venus hypertension in the skin and capillaries of the canine hind limb. Br J Surg 1981; 69:41-14.
35. Browse NL, Burnand KG. The cause of venous ulceration. The Lancet 1982; 2:243-245.
36. Smith PDC, Thomas P, Scurr JH, Dormandy JA. Causes of venous ulceration: a new hypothesis. Br Med J 1988; 296:1726-1727.
37. Thomas P, Nash GB, Dormandy JA. White cell accumulation in dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin. Br Med J 1988; 296:1693-1695.
38. Scott HJ, Smith PDC, Scurr JH. Histological study of white blood cells and their association with lipodermatosclerosis and venous ulceration. Br J Surg 1991; 78:210-211.
39. Wilkinson LS, Bunker C, Edward JCW, Scurr JH, Smith PDC. Leukocytes: their role in the etiopathogenesis of skin damage in venous disease. J Vasc Surg 1993; 17:669-675.
40. Pappas PJ, DeFouw DO, Venezio LM, et al. Morphometric assessment of the dermal microcirculation in patients with chronic venous insufficiency. J Vasc Surg 1997; 26:784-795.
41. Herrick S, Sloan P, McGurk M, Freak L, McCollum CN, Ferguson WJ. Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am J Pathol 1992; 141:1085-1095.
42. Bishop JE. Regulation of cardiovascular collagen deposition by mechanical forces. Molec Med Today 1998; 4:69-75.
43. Higley HR, Kassander GA, Gerhardt CO, Falanga V. Extravasation of macromolecules and possible trapping of transforming growth factor-ß1 in venous ulceration. Br J Surg 1995; 132:79-85.
44. Leu HJ. Morphology of chronic venous insufficiency-light and electron microscopic examinations. Vasa 1991; 20:330-342.
45. Wenner A, Leu HJ, Spycher M, Brunner U. Ultrastructural changes of capillaries in chronic venous insufficiency. Expl Cell Biol 1980; 48:1-14.
46. Peschen M, Lahaye T, Gennig B, Weyl A, Simon JC, Wolfgang V. Expression of the adhesion molecules ICAM-1, VCAM-1, LFA-1 and VLA-4 in the skin is modulated in progressing stages of chronic venous insufficiency. Acta Derm Venereol 1999; 79:27-32.
47. 1 gene expression and protein production. J Vasc Surg 1999; 30:1129-1145.
48. Peschen M, Grenz H, Brand-Saberi B, et al. Increased expression of platelet-derived growth factor receptor alpha and beta and vascular endothelial growth factor in the skin of patients with chronic venous insufficiency. Arch Dermatol Res 1998; 290:291-297.
49. Hasan A, Murata H, Falabella A, et al. Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-ß1. J Dermatol Sci 1997; 16:59-66.
50. Kim B, Kim HT, Park SH, et al. Fibroblasts from chronic wounds show altered TGF-ß signaling and decreased TGF-ß type II receptor expression. J Cell Physil 2003; 195:331-336.
51. Herrick SE, Ireland GW, Simon D, McCollum CN, Ferguson MW. Venous ulcer fibroblasts compared with normal fibroblasts show differences in collagen but not in fibronectin production under both normal and hypoxic conditions. J Invest Dermatol 1996; 106:187-193.
52. Stanley AC, Park H, Phillips TJ, Russakovsky V, Menzoian JO. Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. J Vasc Surg 1997; 26:994-1001.
53. Mendez MV, Stanley A, Park H, Shon K, Phillips TJ, Menzoian JO. Fibroblasts cultured from venous ulcers display cellular characteristics of senescence. J Vasc Surg 1998; 28:876-883.
54. 1 may contribute to chronic venous stasis ulcers. J Vasc Surg 2003; in press.
55. Mendez MV, Stanley A, Phillips TJ, Murphy M, Menzoian JO, Park H. Fibroblasts cultured from distal lower extremities in patients with venous reflux display cellular characteristics of senescence. J Vasc Surg 1998; 28:1040-1050.
56. Weckroth M, Vaheri A, Lauharanta J, Sorsa T, Konttinen YT. Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. J Invest Dermatol 1996; 106:1119-1124.
57. Wysocki AB, Staiano-Coico L, Grinell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101:64-68.
58. Bullen EC, Longaker MT, Updike DL, et al. Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. J Invest Dermatol 1995; 104:236-240.
59. Herouy Y, May AE, Pornschlegel G, et al. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: Implications for venous ulcer formation. J Invest Dermatol 1998; 111:822-827.
60. Herouy Y, Trefzer D, Zimpfer U, Schopf E, Vanscheidt W, Norgauer J. Matrix metalloproteinases and venous leg ulceration. Eur J Dermatol 2000; 9:173-180.
61. Norgauer J, Hildenbrand T, Idzko M, et al. Elevated expression of extracellular matrix metalloproteinase inducer (CD 147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol 2002; 147:1180-1186.
62. Saito S, Trovato MJ, You R, et al. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc Surg 2001; 34:930-938.
63. Herouy Y, Trefzer D, Hellstern MO, et al. Plasminogen activation in venous leg ulcers. Br J Dermatol 2000; 143:930-936.